Download PDF – Cumulative data of three Phase 3 studies demonstrate greater exposure of tivozanib is associated with increased clinical benefit –– Patient Reported Outcomes were numerically better for patients receiving tivozanib in a second line setting versus third line – BOSTON, Feb. 18, 2025 /PRNewswire/ — AVEO Oncology, an LG Chem company (“AVEO”), is
Category: Press Release
AVEO Oncology, an LG Chem company, Announces Tivozanib Presentations at ASCO GU 2025
Download PDF BOSTON, Feb. 12, 2025 /PRNewswire/ — AVEO Oncology, an LG Chem company (“AVEO”), is a biopharmaceutical company that is trying to provide differentiated solutions to improve cancer patients lives, announced today two poster presentations at the upcoming American Society of Clinical Oncology (ASCO) Genitourinary (GU) 2025 meeting this February 13-15, 2025, in San
AVEO Oncology, an LG Chem company, Present TiNivo-2 Results and TIVO-3 Exploratory Post Immunotherapy Survival Analysis at ESMO 2024
Download PDF – TiNivo-2 FOTIVDA® (tivozanib) monotherapy (control arm) results provide clinically meaningful efficacy and safety data following front-line immune checkpoint inhibitor (ICI) combinations – – TIVO-3 Exploratory Overall Survival (OS) Analysis Provides Additional Data for FOTIVDA Following Immunotherapy – – Safety results support the well-established safety profile of FOTIVDA – BOSTON, September 16, 2024
AVEO Oncology, an LG Chem company, Announces Acceptance of Late-Breaking Oral Presentation of TiNivo-2 Results at ESMO 2024
Download PDF BOSTON, September 3, 2024 (PR Newswire) – AVEO Oncology, an LG Chem company (“AVEO”), announced today their late-breaking abstract detailing their Phase 3 TiNivo-2 trial has been selected as a Proffered Paper oral presentation at the 2024 European Society for Medical Oncology (ESMO) Congress in Barcelona, Spain this September 13-17th. The oral presentation
AVEO Oncology, an LG Chem company, Announces Phase 3 Renal Cell Carcinoma Clinical Trial (TiNivo-2) Results
Download PDF – The addition of nivolumab to low dose tivozanib after prior immune checkpoint inhibitor (ICI) is not superior to standard dose tivozanib alone; as a result, the primary endpoint was not met – – Tivozanib monotherapy (control arm) results provide clinically meaningful efficacy and safety data following front-line ICI combinations – – Safety
LG Chem company and AVEO Oncology Announce LG Chem’s First Proprietary Anti-Cancer Compound enters Phase 1 Clinical Study, Dosing Initiated in the U.S.
Download PDF – LG Chem to embark on developing Next-Generation Immune Checkpoint Inhibitors to Provide Solid Tumor Treatment Solutions – – LG Chem and AVEO Oncology continuing to advance its shared vision of becoming a leading global oncology company – BOSTON, June 13, 2024 (PR Newswire) — LG Chem and AVEO Oncology, an LG Chem
CORRECTION – AVEO Oncology Announces Appointment of Chief Medical Officer and Formation of Scientific Advisory Committee
Download PDF – Industry veteran brings extensive clinical development experience to AVEO Oncology leadershipteam as Chief Medical Officer – – Formation of a Scientific Advisory Committee from world-renowned cancer institutions – BOSTON, March 28, 2024 (GLOBE NEWSWIRE) — In a release issued under the same headline on March 25 by AVEO Pharmaceuticals, the text in
AVEO Oncology Announces Publication of Long-Term Survival in Patients With Relapsed/Refractory Advanced Renal Cell Carcinoma Treated With Tivozanib: Analysis of the Phase III TIVO-3 Trial in The Oncologist
Download PDF BOSTON, Feb. 06, 2024 (GLOBE NEWSWIRE) — AVEO Oncology, an LG Chem company (“AVEO”), today announced The Oncologist has published a post-hoc analysis of long-term progression free survival, overall survival and safety data from the Phase 3 TIVO-3 trial evaluating FOTIVDA® (tivozanib) in patients with relapsed or refractory (R/R) advanced renal cell carcinoma
AVEO Oncology Enrolls First Patient in Pivotal FIERCE-HN Clinical Trial to Evaluate Ficlatuzumab in Combination with ERBITUX® (cetuximab) in Patients with HPV-negative Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma (R/M HNSCC)
Download PDF BOSTON, Jan. 16, 2024 (GLOBE NEWSWIRE) — AVEO Oncology (“AVEO”), an LG Chem company, today announced enrollment of the first patient in the FIERCE-HN trial, a global, multicenter, randomized, double-blind, placebo-controlled, phase 3 clinical trial evaluating ficlatuzumab in combination with ERBITUX® (cetuximab), an anti-EGFR antibody, in patients with human papillomavirus (HPV)-negative recurrent or
AVEO Oncology, an LG Chem company, Earns Spot on Boston Globe’s 2023 Top Places to Work List for Second Consecutive Year
Download PDF Boston, MA (November 30, 2023) — For the second year in a row, AVEO Oncology, an LG Chem company, has earned a spot on the Boston Globe’s annual ‘Top Places to Work in Massachusetts’ list. AVEO Oncology appears in the medium-sized company (100-249 employees) category. “We are incredibly excited to be selected once